Trial Profile
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Imetelstat (Primary) ; Antineoplastics; Corticosteroids; Danazol; Hydroxycarbamide; Interferon; Thalidomide
- Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
- Focus Registrational; Therapeutic Use
- Acronyms IMpactMF
- Sponsors Geron Corporation
- 06 Dec 2023 According to Geron Corporation media release, the company announces achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial
- 11 Aug 2023 Planned End Date changed from 27 Aug 2025 to 27 Apr 2026.
- 11 Aug 2023 Planned primary completion date changed from 27 Aug 2025 to 27 Apr 2026.